Low-frequency transcranial stimulation of the pre-supplementary motor area was found to delay the onset and reduce severity of levodopa-induced dyskinesia in patients with Parkinson disease.

PD affects an estimated 1 million people in the United States, with approximately 60,000 people newly diagnosed each year. 1 The prevalence increases with age, and because of the growing aging ...

SYDNEY, Australia — Treatment with a proprietary investigational extended-release version of amantadine (ADS-1502, Adamas Pharmaceuticals) led to a statistically significant improvement in the ...

Learn about dyskinesia, including its causes, symptoms, types, and available treatment options to help manage involuntary ...

Levodopa is the standard therapy for Parkinson disease (PD), but prolonged use is associated with uncontrollable chorea-like movements or dyskinesia. Excessive levels of striatal dopamine are thought ...

For patients with Parkinson's disease (PD) who have levodopa-induced dyskinesia (LID), amantadine can maintain its antidyskinetic effect over several years, a new study indicates. The finding goes ...

Nine MPTP-intoxicated monkeys with stable parkinsonism received levodopa for several months at a dose designed to produce a full reversal of their parkinsonian condition. Five of nine levodopa-treated ...

On February 10, 2015, Amarantus Bioscience Holdings, Inc. (AMBS) announced the publication of Phase 2a results of eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia ...

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund ...

EMERYVILLE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (ADMS) today announced that its Phase 3 EASE LID clinical trial evaluating the company's investigational compound ADS ...

Levodopa is the preferred treatment in the clinic for Parkinson's disease. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the ...

After five to ten years on levodopa, the gold-standard drug for Parkinson’s disease, up to 80 percent of patients develop a cruel trade-off: the medication that restores their ability to move also ...